Mapi Pharma GA Depot Shows Strong MS Progression Control
NESS ZIONA, Israel, April 16, 2026 Mapi Pharma Ltd. has announced new clinical findings demonstrating that its Glatiramer Acetate...
Neurology
Advertisement
Neurelis Shows Strong Seizure Control Data for VALTOCO at AAN
SAN DIEGO, Calif., April 16, 2026 Neurelis, Inc. has announced new clinical and real-world analyses demonstrating the effectiveness of...
MemorialCare Joins FASTEST Trial for Stroke Therapy
LONG BEACH, Calif., April 2026 MemorialCare Long Beach Medical Center has joined a nationwide Phase 3 clinical research effort...
Rapport Presents Phase 2 Data for Epilepsy Drug RAP-219
BOSTON & SAN DIEGO, USA — April 1, 2026 Rapport Therapeutics, Inc. announced that it will present new Phase...
Ionis Zilganersen NDA Gets FDA Priority Review
CARLSBAD, California, March 23, 2026 Ionis Pharmaceuticals has announced that the U.S. Food and Drug Administration (FDA) has accepted...
Advertisements
Vasomune AV-001 Trial Begins for Brain Protection
TORONTO, CANADA | March 24, 2026 A significant milestone has been reached in clinical-stage biopharmaceutical research as the first...
LT3001 Stroke Drug Shows Phase 2 Functional Gains
Taipei, Taiwan — February 6, 2026 Lumosa Therapeutics has announced positive Phase 2 clinical trial outcomes for LT3001 (odatroltide),...
FDA Clears Neurophet AQUA AD Plus in Alzheimer’s AI
Seoul, South Korea — February 6, 2026 Neurophet has announced that the U.S. Food and Drug Administration (FDA) has...
AEON Biopharma Posts Q3 Gains with Strong ABP-450 Biosimilarity Data
IRVINE, CA — November 14, 2025 — AEON Biopharma announced its third-quarter 2025 financial results, highlighting strong operational progress,...
Gate Bioscience Raises $65M to Advance Molecular Gates
BRISBANE, CA – November 13, 2025 — Gate Bioscience announced the closing of an oversubscribed $65 million Series B...
Advertisement
